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Abstract
Aims Cardiac involvement is the main determinant of poor outcomes in sarcoidosis. Right ventricular (RV) dysfunction
and left ventricular (LV) late gadolinium enhancement (LGE) have been reported to be predictive of adverse outcome
in non-ischaemic cardiomyopathies. The aim of our study was to determine whether delayed RV LGE with cardiovascular
magnetic resonance would be predictive of adverse events in addition to LV LGE during the long-term follow-up of pulmonary
sarcoidosis patients.
Methods and results Eighty-four consecutive biopsy-proven pulmonary sarcoidosis patients were followed for a median of
56 months [38–74] after baseline delayed contrast-enhanced cardiac magnetic resonance. The composite primary endpoint
consisted of admission for congestive heart failure, sustained ventricular tachycardia, appropriate implantable cardioverter
deﬁbrillator therapy, pacemaker implantation for high degree atrio-ventricular block, or cardiac death. The composite secondary
endpoint included all-cause mortality in addition to the primary endpoint. RV and LV LGE were demonstrated in respectively 12
and 27 patients. Five of 10 events included in the primary endpoint occurred in the group with RV LGE. RV LGE, LV, or
biventricular LGE yielded Cox hazard ratios of 8.71 [95% conﬁdence interval (CI) 1.90–23.81], 9.22 (95% CI 1.96–43.45), and
12.09 (95% CI 3.43–42.68) for the composite primary endpoint. In a multivariate model, the predictive value of biventricular
LGE for the composite primary and secondary endpoints was strongest. Kaplan–Meier event-free survival curves were most
signiﬁcant for RV LGE and biventricular LGE (log rank with P < 0.001).
Conclusions Biventricular LGE at presentation is the strongest, independent predictor of adverse outcome during long-term
follow-up. Asymptomatic myocardial scar <8% of LV mass carried a favourable long-term outcome.
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Introduction
Sarcoidosis is a rare inﬂammatory condition of unknown
aetiology, which results in granulomatous inﬁltration and
focal myocardial scar in approximately a third of patients.
Major cardiac morbidity or mortality has been reported in
approximately 5–10% of sarcoidosis patients.1 Diagnosing
cardiac sarcoidosis (CS) can be challenging, and several non-
invasive diagnostic imaging modalities have been used over
the years. Recently, delayed contrast-enhanced cardiac mag-
netic resonance (DECMR) and positron electron tomography
(PET) showed most diagnostic and prognostic promise.2–15
DECMR has become the gold standard test for detecting
and quantifying focal myocardial scar, a predictor of high
degree atrio-ventricular block (AVB), heart failure [congestive
cardiac failure (CCF)], ventricular tachycardia (VT), and
sudden cardiac death (SCD) in CS.2–8,10–15 (Table 1A and 1B)
Systolic right ventricular (RV) impairment and multi-focal RV
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late gadolinium enhancement (LGE) on cardiovascular
magnetic resonance (CMR) and active RV granulomatous
inﬂammation on PET have been associated with adverse
outcomes in retrospective studies.2,7,11,12,16–18 We
previously demonstrated the diagnostic accuracy of
DECMR for CS and reported on RV involvement in
pulmonary sarcoidosis utilizing CMR.19,20 We currently report
on the prognostic value of RV LGE in addition to left ventric-
ular (LV) LGE in patients suffering from pulmonary
sarcoidosis.
Methods
Patient population
Between July 2001 and August 2010, we prospectively
followed 84 consecutive patients with histologically proven
pulmonary sarcoidosis. These patients had been referred
for cardiac evaluation, either because of cardiac symptoms
(palpitations, congestive heart failure, (pre)syncope, and
chest discomfort) or for routine cardiac assessment
(Figure 1). Patients were excluded in case of standard
contraindications to DECMR. Approval for our project
was obtained from the local Institutional Review Board.
Cardiovascular magnetic resonance protocol
The CMR studies were performed using a commercial 1.5 T
magnetic resonance scanner with a cardiac-dedicated,
phased-array coil. The CMR studies were electrocardiogram
(ECG) triggered by standard software. Studies consisted of
multi-phase, multi-slice, steady-state free precession and
fat-saturated T2-weighted spin echo (64 patients) breath-
hold sequences of the short-axis, vertical long-axis, and hori-
zontal long-axis views. The short-axis images covered the LV
and RV from base to apex. The steady-state free precession
sequences (typical repetition time: 3.5 ms; echo-time
1.4 ms; ﬂip-angle 55°, temporal resolution 50 ms, voxel size
1.6 × 1.6 × 10 mm, no gap) were performed to assess regional
wall-motion abnormalities, ventricular volumes, masses, and
ejection fractions [left ventricular ejection fraction (LVEF)
and right ventricular ejection fraction (RVEF)]. T2-weighted
studies were performed to assess for the presence of myocar-
dial inﬂammation. Contrast-enhanced and T2-weighted im-
ages were obtained in diastole to minimize artefact due to
cardiac motion. Ten minutes after the additional administra-
tion of 0.1 mmol/kg gadolinium-diethylenetriaminepenta-
acetic acid (Schering, Berlin, Germany), a two-dimensional
segmented inversion recovery-gradient echo breath-hold se-
quence (short axis, vertical long axis, and horizontal long axis,
voxel size 1.6 × 1.6 × 10 mm, without gap), was used to assess
for LGE. The inversion time (250 to 400 ms) was determined
on an individual basis to obtain optimal nulling of the
unenhanced myocardial signal.
Cardiovascular magnetic resonance analysis
The CMR studies were analysed ofﬂine by two experienced
blinded observers who independently evaluated the study
ﬁndings using commercially available software (CAAS MRV
3.4, Pie Medical Imaging, Maastricht, the Netherlands).
Endocardial and epicardial contours were manually delin-
eated in end-diastolic and end-systolic short-axis slices to
determine LV and RV end-diastolic volumes (LVEDV and
RVEDV), end-systolic volume, LVEF, RVEF, and LV and RV
end-diastolic masses, which were indexed to body surface
area. The presence and distribution of LGE and increased
T2 signal were determined by consensus, and LV LGE was
localized according to the 17-segment model. LGE was con-
sidered present only if conﬁrmed on both short-axis and
matching long-axis myocardial locations. LGE was quantiﬁed
by a semi-automatic detection method using the signal
intensity threshold of ≥2 SD above a remote reference
region. The distribution of LGE was characterized as sub-
endocardial, mid wall, sub-epicardial, patchy, or conﬂuent
transmural. When more than one pattern was present, the
distribution was characterized on the basis of the predomi-
nant pattern. There was excellent intraobserver and interob-
server correlation for ventricular volumes, masses, and
ejection fractions. Interobserver agreement when determin-
ing the presence/localization of LGE was good (kappa 0.85,
P < 0.001). The intra-class correlation coefﬁcient for LV
LGE was 0.989 [0.981–0.993] (P = 0.001).
Clinical follow-up
Scheduling of follow-up visits was 4–6 monthly and left at the
discretion of the managing clinician. Resting 12-lead surface
ECGs and 24–72 h ambulatory ECGs were performed and
evaluated for intermittent intra-ventricular or atrio-
ventricular conduction disease and/or ventricular arrhyth-
mias. Sustained VT (sVT) was deﬁned as VT with a rate
>100 beats/min, lasting for at least 30 s. Implanted
cardioverter deﬁbrillators (ICD) or pacemakers (PM) were in-
terrogated every 4 months and assessed for ventricular ar-
rhythmias. At regular intervals and at the end of our study,
outcome data were collected from the family physician and
managing specialist.
Variables, deﬁnitions, adverse events, and
composite endpoints
The composite primary endpoint consisted of newly devel-
oped AVB resulting in PM implantation, admission for CCF,
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sVT, appropriate ICD therapy for sVT or ventricular ﬁbrillation
(VF), or cardiac death. Appropriate ICD therapy was deﬁned
as anti-tachycardia pacing (ATP) or shock for fast VT (R-R
<320 ms) or VF. The composite secondary endpoint
included all-cause death in addition to the primary endpoint.
Peak systolic RV pressures over 40 mmHg were considered
Figure 1 (A) Flow diagram of the baseline ﬁndings and adverse events during follow-up included in the primary composite endpoint up in 84 sarcoid-
osis patients. (B) Flow diagram that demonstrates adverse outcomes as related to the ﬁndings with basic evaluation [electrocardiogram (ECG)/Holter/
cardiac ultrasound (CUS)] and delayed contrast-enhanced cardiac magnetic resonance. AVB, atrio-ventricular block; CCF, congestive cardiac failure;
DECMR, delayed contrast-enhanced cardiac magnetic resonance; ECG,electrocardiogram; FU, follow-up; ICD, implantable cardioverter deﬁbrillator;
LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; PES,
programmed electrical stimulation; PM, pacemaker; RV, right ventricle; RVEF, right ventricular ejection fraction; SCD, sudden cardiac death; sVT,
sustained ventricular tachycardia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
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to represent pulmonary hypertension. RV end-diastolic wall
thickness over 5 mm was considered evidence of RV
hypertrophy. RV dysfunction was deﬁned as an RVEF <45%
by CMR.21
Statistical analysis
All statistical analyses were performed using statistical soft-
ware (Version 21.0, SPSS; Chicago, IL). Continuous normally
distributed data were expressed as mean ± SD, and
between-group comparisons were made using the paramet-
ric t-test for independent samples or Mann–Whitney U test
when appropriate. In non-normally distributed continuous
data, the median and interquartile ranges were deter-
mined, and between-group comparisons were made with
the Wilcoxon test. Categorical variables were assessed
using the χ2 or Fisher’s exact test when appropriate. Linear
regression analysis was used to determine the relationship
between LGE, LVEDV, and LVEF. Univariate analyses of the
risk for adverse outcome associated with selected variables
were performed with the Cox proportional hazards model.
A P value of <0.05 was considered statistically signiﬁcant.
The hazard ratio (HR) for the prediction of events was cal-
culated for each of the outcomes using a multivariable Cox
regression model; two-tailed values of P < 0.05 were con-
sidered signiﬁcant. Composite event curves were
determined according to the Kaplan–Meier method, and
comparisons of cumulative event rates were performed
using the log-rank test. Receiver operating characteristic
(ROC) curves were used to examine the performance char-
acteristic of %LGE mass. Area under the curve, and 95%
conﬁdence of the ROC curve, was calculated to provide a
measure of the accuracy of %LGE mass to predict com-
bined adverse outcomes.
Results
Patient characteristics
Figure 1 and Table 2 demonstrate the baseline characteristics
of the included 84 patients. Twenty-nine patients had CS ac-
cording to the Heart Rhythm Society (HRS) criteria, 18 accord-
ing to the Japanese Ministry of Health and Welfare criteria.22
Twenty-ﬁve (30%) patients presented with cardiac symptoms
(palpitations, (pre)syncope, chest discomfort, and congestive
heart failure), while the remaining 59 patients (70%) experi-
enced non-speciﬁc symptoms (fatigue) or were routinely
screened for CS. According to the American College of
Cardiology/American Heart Association/HRS 2008 guidelines
for device-based therapy of cardiac rhythm abnormalities,
Figure 1 Continued.
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an ICD or PM were implanted in respectively 14 (four
ICD/biventricular PM) and two patients after the baseline
DECMR study.23 Heart failure was managed according to cur-
rent optimal practice.
Cardiovascular magnetic resonance ﬁndings
The ﬁndings with DECMR are displayed in Table 3. Twelve
patients (44%) had RV LGE, predominantly involving the
right-sided interventricular septum and/or ventricular in-
sertion points. Two patients had isolated RV LGE. Patients
with RV LGE had signiﬁcantly more %LV LGE than those
without RV involvement [32% (23–41) vs. 10% (2–18),
P = 0.006], and RV LGE correlated with the presence of
pulmonary hypertension (P = 0.022), RV hypertrophy
(P = 0.050), and impaired RV function (P < 0.001).
The LGE involved 4–39% of LV mass, and predominantly in-
volved the interventricular septum, and basal LV segments.
LGE was equally distributed over the three myocardial layers
and was patchy (56%) or conﬂuent transmural (44%). In 16
patients (59%), three myocardial layers were involved. In
12% of patients (7/59) who were routinely evaluated, asymp-
tomatic myocardial scar was present, though signiﬁcantly
smaller when compared with the symptomatic group [8%
(4–20) vs. 28% (8–39), P = 0.001). LGE strongly correlated
with the presence of cardiac symptoms, ECG abnormalities,
VT, LVEDV, and LVEF (P < 0.001). The transmural extent of
LGE correlated with segmental wall-motion abnormalities
(P < 0.001). Linear regression analysis demonstrated a de-
crease in LVEF of 7.27% for every 10% increase in LGE (r2
0.392, P value < 0.001, 95% CI, 5.25% to 9.30%). For ev-
ery 10% increase in LGE, the LVEDV increased 9.1 mL in vol-
ume (r2 0.239, P < 0.001, 95% CI 5.27–12.92 mL). In
patients with sVT at presentation, the median LVEF was sig-
niﬁcantly poorer, and LV mass, LVEDV index, and %LV LGE
are signiﬁcantly higher when compared with those
without sVT at presentation [respectively 60% (53–67) vs.
51% (34–68) (P = 0.001), 55 (44–66) vs. 73 mL (50–95)
(P = 0.011), 111 (80–142) vs. 145 g (95–195) (P =0.028), and
14% (range 2–38) vs. 33% (22–55) (P = 0.016)].
Follow-up results
Figures 1A and 1B and illustrate the baseline ﬁndings and
outcomes. During a median follow-up of 56 months
(1–90 months), eight patients (30%) with LGE experienced
an adverse event. All adverse cardiac events occurred in
patients who had presented with cardiac symptoms. A
57-year-old woman (New York Heart Association class 3,
non-dilated, scarred LV, LV LGE 32%, and non-sustained
VTs at rest) awaiting elective ICD implantation experienced
SCD, one patient was admitted because of CCF, and six
patients had appropriate ICD therapy/discharge for sVT/VF.
Table 2 Patients’ baseline characteristics
All patients with follow-up 84 (100)
Female 54 (64)
Caucasian 63 (75)
Age, years 53.3 ± 9.8
Diabetes mellitus 3 (4)
Hypertension 7 (8)
Cardiac presentation 25 (30)
Syncope 4 (5)
Palpitations 9 (11)
Clinical congestive heart failure 8 (10)
Dyspnoea NYHA class 0 50 (59)
NYHA class 1–2 29 (35)
NYHA class 3–4 5 (6)
Sustained ventricular tachycardia 10 (12)
Aborted sudden cardiac death 1 (1)
Chest discomfort 3 (4)
Abnormal electrocardiogram 26 (31)
Pulmonary arterial hypertension 14 (17)
Medication at any time
Steroids 60 (71)
Methotrexate 6 (7)
Loop diuretics 10 (12)
Spironolactone 10 (12)
ACE inhibitors/ATIIRB 11 (13)
Beta-blockers 13 (16)
Amiodarone 15 (18)
CMR imaging parameters
LVEF, % 60 [14–84]
Impaired LVEF (≤50%) 16 (19)
Impaired LVEF with LGE 13 (15)
Impaired RVEF (≤45%) 19 (18)
LVEDV, mL 112 [88–136]
LVEDV index, mL/m2 58 [47–70]
LV dilation 8 (10)
LV mass, g 116 [90–142]
LV mass index, g/m2 64 [44–84]
LVH 22 (26)
LV LGE present 27 (32)
LV LGE, g 20 [8–45]
LV LGE, % of LV mass 15 [6–33]
RVEF, % 47 [40–54]
RVEDV, mL 140 [97–183]
RVEDV index, mL/m2 78 [58–98]
RV dilation 13 (15)
RV mass, g 43 [34–52]
RV mass index, g/m2 23 [18–28]
RVH 11 (11)
RV LGE present 12 (14)
T2 positive 10/69 (14)
Follow up, months 59.0 ± 22.2 [3–108]
Cardiac events during follow-up 10 (12)
Cardiac death 1 (1)
Admission for congestive
heart failure
1 (1)
Appropriate ICD therapy 7 (8)
Atrio-ventricular block, pacemaker
implantation
1 (1)
Time to events, months 6 (1–80)
ACE, angiotensin-converting enzyme; ATIIRB, angiotensine receptor
blocker; CMR, cardiac magnetic resonance; EDV, end-diastolic
volume; ICD, implantable cardioverter-deﬁbrillator; LGE, late
gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; LVH,
left ventricular hypertrophy; NYHA, New York Heart Association;
RV, right ventricle; RVEF, right ventricular ejection fraction; RVH,
right ventricular hypertrophy
Values are n (%), median [IQR], or mean ± SD.
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The average annualized ICD therapy rate was 11.1%. Three
layer conﬂuent transmural LGE predicted arrhythmic events
(P = 0.018) and the composite primary endpoint
(P = 0.003). VT at inclusion or during follow-up did not cor-
relate with any speciﬁc localization grouping of LGE, such as
basal septal LGE. Two patients, one presenting with palpita-
tions and the other with pre-syncopal symptoms, both with-
out LGE (2/57, 4%) or T2 signal, suffered an adverse event,
respectively sVT after 10 months and PM implantation for
third degree AVB after 6 months. Endpoints occurred up
to 80 months after baseline CMR. Three patients died of
non-cardiac conditions, respectively sepsis, respiratory fail-
ure due to extensive pulmonary ﬁbrosis, and malignancy.
None of the patients with non-speciﬁc symptoms, such as
fatigue, who had been routinely evaluated for cardiac in-
volvement and had LGE [7/59 (12%), LV LGE 5.9 ± 3.8%] de-
veloped adverse cardiac events during follow-up.
Predictors of events
Table 4 demonstrates the predictors of adverse events in
our study. RV, LV, and biventricular LGE were the stron-
gest predictors for adverse events. Six of eight arrhythmic
endpoints occurred in patients with LVEF > 35%. Univari-
ate Cox regression analysis found RV LGE 8.71 (95% CI
Table 3 Characteristics of patients with and without late gadolinium enhancement
LGE  n = 56 LGE + n = 28 P value OR (95% CI)
Female 19 (34) 11 (39) 0.638
Caucasian 42 (75) 21 (75) 1
Age, years 52.4 ± 10.1 55.3 ± 8.9 0.37
Cardiac presentation 5 (9) 20 (71) <0.001 29.71 (8.44–104.60)
Syncope 1 (2) 3 (11) 0.096 7 (0.69–70.74)
Palpitations 2 (4) 7 (26) 0.004 9.60 (1.84–50.25)
Clinical congestive heart failure 2 (4) 6 (21) 0.012 7.86 (1.47–42.04)
Sustained ventricular tachycardia 3 (5) 7 (25) 0.011 6.30 (1.483–26.765)
Aborted sudden cardiac death 0 1 (4) 0.321 1.13 (0.99–0.129)
Chest discomfort 0 3 (11) 0.031
Dyspnoe NYHA 0–2 55 (96) 26 (93) 0.96
NYHA 3–4 2 (4) 1 (4) 1
Diabetes mellitus 3 (5) 0 0.548
Hypertension 6 (11) 1 (4) 0.420
Medication at any time
Steroids 36 (63) 24 (86) 0.019
Methotrexate 1 (2) 5 (18) 0.012
Loop diuretics 2 (4) 8 (29) 0.001
Spironolactone 2 (4) 8 (29) 0.001
ACE inhibitors/ATIIRB 1 (2) 10 (36) <0.001
Beta–blockers 2 (4) 11 (39) <0.001
Amiodarone 2 (4) 12 (43) <0.001
Pulmonary arterial hypertension 5 (9) 9 (32) 0.010 5.100 (1.508–17.243)
CMR imaging parameters
LVEF % 64 [50–70] 55 [49–72] <0.001
LVEDV, mL 111 [91–131] 132 [92–172] 0.02
LVEDV index, mL/m2 55 [48–62] 71[49–93] 0.007
LV mass 114 [94–134] 122 [92–152] 0.599
LV mass index, g/m2 64 [44–84] 64 [43–85] 0.363
LVH 26 (46) 15 (54) 0.410
LV dilation 3 (5) 11 (39) <0.001 11.216 (2.796–44.988)
LVEF ≤50% 3 (5) 13 (48) <0.001 11.842 (2.342–59.879)
RVH 4 (7) 7 (25) 0.029 4.333 (1.147–16.366)
RV mass 39 [32–46] 42 [35–49] 0.753
RV mass index, g/m2 22 [16–28] 23 [20–26] 0.964
RV ≤45% 6 (11) 13 (48) 0.011 7.222 (2.342–22.276)
RVEF % 48 [42–54] 46 [36–56] 0.288
RVEDV, mL 185 [143–227] 183 [140–226] 0.084
RVEDV index, mL/m2 81 [61–101] 96 [69–123] 0.028
T2 positive 1/45 (2) 9/24 (38) <0.001 24.188 (2.834–206.451)
Follow up, months 52.4±22.1 61.7±21.5 0.62
Events during follow–up 2 (4) 8 (30) 0.001
Time to event, months 8 (6–10) 4.5 (1–80) 0.701
Values are n (%), median [IQR], or mean ± SD. Values are for all patients with sarcoidosis (84).
ACE, angiotensin-converting enzyme; CI, conﬁdence interval; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; LV,
left ventricle; LVEDV, left ventricular end-diastolic volume; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association; OR, odds ratio; RV, right ventricle; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular
ejection fraction; RVH, right ventricular hypertrophy. Bold numbers are the statistically signiﬁcant (P < 0.05) correlations.
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1.90–23.81), LV LGE [HR 9.22 (95% CI 1.96–43.45)], and
biventricular LGE [HR 12.09 (95% CI 3.43–42.68] to be
the strongest predictors of the composite primary end-
point. Multivariate Cox regression analysis, including CCF,
LV LGE, biventricular LGE, any LGE, LGE with systolic ven-
tricular dysfunction, LV dilation, and LV or RV systolic dys-
function, revealed biventricular LGE to be the best
independent predictors of the composite primary and sec-
ondary endpoints at follow-up (P < 0.001, HR 10.2, 95%
CI 2.92–35.71, respectively, P = 0.001, HR 6.80, 95% CI
2.19–21.28). None of the other parameters reached statis-
tical signiﬁcance. The Kaplan–Meier event-free survival
curves found RV LGE, LV LGE [log rank (Mantel Cox)
P = 0.001], and biventricular LGE [log rank (Mantel Cox)
P ≤ 0.001] as the strongest predictors for the composite
primary endpoint. RV LGE and biventricular LGE were
the strongest predictors for the composite secondary end-
point [log rank (Mantel Cox) P ≤ 0.001] (Figure 2).
Table 4 Univariate analysis for association with the primary composite endpoint
No endpoints n = 74 Primary composite endpoint n = 10 P value OR (95% CI)
Female 48 (65) 6 (60) 0.76 0.81 (0.21–3.14)
Caucasian 56 (76) 7 (70%) 0.70 0.75 (0.175–3.21)
Age, years 53 ± 10 55 ± 7 0.66
Cardiac presentation 15 (20) 10 (100) <0.001 12.44 (3.037–50.994)
Syncope 2 (3) 2 (20) 0.02 9.00 (1.11–72.88)
Palpitations 4 (5) 5 (50) <0.001 17.50 (3.54–86.46)
Clinical congestive heart failure 5 (7) 3 (30) 0.02 5.91 (1.16–30.15)
Sustained ventricular tachycardia 6 (8) 5 (50) <0.001 11.33 (2.54–50.51)
Aborted sudden cardiac death 1 (1) 0 0.71
Chest discomfort 3 (4) 0 0.52
Dyspnoea NYHA class 0–2 72 (97) 9 (90) 0.24 4 (0.33-48.66)
NYHA class 3–4 2 (3) 1 (10) 0.24
Diabetes mellitus 3 (4) 0 0.52
Hypertension 7 (9) 0 0.31
Medication at any time
Steroids 51 (69) 9 (90) 0.17
Methotrexate 5 (7) 1 (10) 0.71
Loop diuretics 6 (8) 4 (40) 0.003
Spironolactone 6 (8 ) 4 (40) 0.003
ACE inhibitors/ATIIRB 6 (8) 5 (50) <0.001
Beta–blockers 5 (7) 8 (80) <0.001
Amiodarone 7 (9) 8 (80) <0.001
ECG abnormalities at presentation 19 (26) 7 (70) 0.004 6.75 (1.59–28.78)
Pulmonary Hypertension 9 (12) 5 (50) 0.039 4.24 (1.133–15.833)
CMR imaging parameters
LVEF % 55 [48–62] 50 [35–65] 0.01
LVEDV, mL 111 [88–134] 139 [107–171] 0.02
LVEDV index, mL/m2 58 [38–78] 81 [64–98] 0.02
LVEF < 50% 11 (15) 5 (50) 0.01 5.36 (1.33–21.68)
LVEF ≤ 35% 3 (4) 2 (20) 0.06 5.58 (0.81–38.60)
LV dilation 5 (7) 3 (30) 0.02 5.83 (1.44–29.72)
LVH 17 (23) 5 (50) 0.12
LV mass 106 [84–128] 189 [151–227] 0.004
LV LGE present 12 (4–74) 49 [32–66] <0.001 11.58 (2.26–59.39)
LV LGE, % of LV 14 [3–36] 28 [20–36] <0.001
LV LGE with systolic impairment 8 (11) 5 (50) 0.001 8.25 (1.95–34.84)
RV LGE present 6 (8) 6 (60) 0.002 9.29 (2.350–36.696)
Biventricular LGE 5 (7) 5 (50) 0.004 10.47 (2.323–47.171)
RVH 7 (9) 4 (40) 0.062 4.10 (0.989–16.691)
RV mass 42 [33–51] 50 [38–62] 0.305
RV mass index, g/m2 22 [17–27] 25 [19–31] 0.1993
RV dysfunction 14 (19) 5 (50) 0.042 3.82 (1.101–13.285)
RVEF % 47 [41–53] 47 [32–62] 0.793
RVEDV 140 [98–182] 137 [93–187] 0.785
RVEDV index, mL/m2 77 [57–97] 84 [61–107] 0.431
T2 positive 7/52 (13) 3/7 (43) 0.13 3.18 (0.67–15.24)
Follow up, months 53 ± 20 71 ± 33 0.01
Time to event, months 14.3 (1–80)
ACE, angiotensin-converting enzyme; CI, conﬁdence interval; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gado-
linium enhancement; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVH, left ven-
tricular hypertrophy; NYHA, New York Heart Association; OR, odds ratio; RV, right ventricle; RVEF,right ventricular ejection fraction; RVH,
right ventricular hypertrophy. Bold numbers are the statistically signiﬁcant (P < 0.05) correlations.
Values are n (%), median [IQR], or mean ± SD.
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Figure 2 (A) Kaplan–Meier survival curve for LV LGE (composite primary endpoint). (B) Kaplan–Meier survival curve for biventricular LGE (composite
primary endpoint). (C) Kaplan–Meier survival curve for any myocardial LGE (composite primary endpoint). (D) Kaplan–Meier survival curve for RV
dysfunction (composite primary endpoint). (E) Kaplan–Meier survival curve for RV LGE (composite primary endpoint). (F) Kaplan–Meier survival curve
for RV LGE (composite secondary endpoint). CMR, cardiovascular magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricle; RV, right
ventricle.
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In the present patient population, ROC curve analysis
indicated that %LV LGE had the modest ability to predict
the composite primary adverse outcome (area under the
curve = 0.77, 95% CI 0.58–0.95). A cut-off level of 7%
LV LGE best predicted combined adverse cardiac out-
comes, with a sensitivity of 70% and a speciﬁcity of
85%. The test’s positive and negative predictive values
were 39% and 95%, respectively. Figures 3–6 demonstrate
LGE in symptomatic patients with and without adverse
events during follow-up.
One appropriate shock would be delivered for every 2.5
implanted ICDs in sarcoidosis patients, when based on the
combination of cardiac symptoms, abnormal ECG and/or
rhythm monitoring, and biventricular LGE or LGE > 7% of
LV mass.
Discussion
Our ﬁndings demonstrate that the extent and distribution of
myocardial LGE in a cohort of predominantly middle-aged
Caucasian women with chronic pulmonary sarcoidosis corre-
lates with ventricular volumes and systolic impairment and
Figure 3 Delayed contrast-enhanced cardiac magnetic resonance of a middle-aged female patient who presented in CCF with frequent non-
sustained ventricular tachycardia, left bundle branch block, left ventricular ejection fraction 38% and extensive patchy late gadolinium enhance-
ment [38% left ventricular (LV) mass], predominantly involving the right-sided interventricular septum, right ventricular (RV) free wall, and LV
mid-epicardial and sub-epicardial layers (arrows). A biventricular pacemaker/implantable cardioverter deﬁbrillator was implanted. During follow-
up of 62 months, no adverse events occurred. (A) Inversion Recovery-Gradient Echo sequence, short-axis view; (B) Inversion Recovery-Gradient
Echo sequence, horizontal long-axis view; (C) T2 weighted spin echo sequence–increased signal signiﬁes inﬂammation of the RV free wall and
LV apex.
Figure 4 Delayed contrast-enhanced cardiac magnetic resonance in a patient with preserved systolic left ventricular (LV) function, who presented
with dyspnoea and palpitations demonstrating predominantly apical late gadolinium enhancement (arrows) (left ventricular late gadolinium en-
hancement 8%). Holter monitoring detected frequent episodes of non-sustained ventricular tachycardia. 111Indium-pentetreotide scintigraphy
demonstrated active apical inﬂammation. An implantable cardioverter deﬁbrillator was implanted, and immune-suppressive and anti-arrhythmic
therapy was initiated. (A) Inversion Recovery-Gradient Echo sequence, horizontal long-axis view; (B) Inversion Recovery-Gradient Echo, vertical
long-axis view.
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most signiﬁcantly predicts adverse (arrhythmic) outcome.
Our study is the ﬁrst to prospectively detail RV assessment
and include T2-weighted assessment in the majority of
patients (Table 1B).
Recently, systolic RV impairment, multi-focal RV LGE, and
active RV granulomatous inﬂammation in CS were associated
with LV LGE, sVT, and death.2,7,11,12,16–18 Our study is the ﬁrst
to demonstrate the direct relationship between RV LGE, RV
Figure 5 The implanted implantable cardioverter deﬁbrillator detected episodes of sustained ventricular tachycardia after 18 months. The top strip
demonstrates unsuccessful implantable cardioverter deﬁbrillator discharge for fast monomorphic ventricular tachycardia (VT), with eventual ventric-
ular ﬁbrillation (VF) successfully reverted to a paced rhythm.
Figure 6 Delayed contrast-enhanced cardiac magnetic resonance of a middle-aged male patient who presented with pre-syncopal symptoms because
of sustained ventricular tachycardia originating from the right ventricle (RV). Delayed contrast-enhanced cardiac magnetic resonance demonstrated
extensive patchy left ventricle (LV), in addition to late gadolinium enhancement of the inferior RV segments and inferior RV insertion point (arrows).
Anti-arrhythmic and immune suppressive treatment was started, and an implantable cardioverter deﬁbrillator was implanted. Programmed electrical
stimulation on treatment was unable to elicit any monomorphic ventricular tachycardia. During follow-up of 79 months, no adverse events occurred.
(A) and (B) Inversion Recovery-Gradient Echo sequence, short-axis views.
168 J.-P. Smedema et al.
ESC Heart Failure 2018; 5: 157–171
DOI: 10.1002/ehf2.12201
volumes, RV systolic impairment, sVT, and death of all cause.
In the absence of data on VT morphology, it remains unclear
whether the prognostic relevance of RV LGE is related to
more extensive biventricular arrhythmogenic substrate or
whether RV LGE itself is particularly arrhythmogenic.18,24
None of our patients with asymptomatic LGE suffered ad-
verse cardiac events, while the majority of arrhythmic end-
points (75%) occurred in patients with LVEF > 35%. Our
ﬁndings support the ﬁndings of several recent studies, which
evaluated the risk of SCD in CS patients and also recorded ap-
propriate ICD therapy in a large proportion of patients with
LVEF > 35%.4,7,12,22
The risk of VT and SCD in CS seems primarily related to
amount and distribution of granulomas and scar and not
the systolic function. Arrhythmic substrate imaging with
DECMR and/or PET determines the risk of arrhythmic events
more accurately than LVEF.2,4,7,12,17,18,22,24 The negative pre-
dictive value of LGE negative DECMR is excellent, with only
one patient with LV LGE < 8% developing an arrhythmic
event after 10 months of follow-up. In the absence of pro-
spective data, it seems prudent to follow asymptomatic sar-
coidosis patients up with ECG and cardiac ultrasound and
evaluate suspected or conﬁrmed CS with PET and/or
DECMR.22 Ongoing research will determine the optimal study
follow-up interval. By reserving DECMR for sarcoidosis pa-
tients with cardiac symptoms, and/or abnormalities on basic
assessment (resting ECG, ambulatory rhythm monitoring,
and/or cardiac ultrasound), and implanting ICDs in patients
with LGE ≥ 7%, costs could be contained and beneﬁt opti-
mized—in our study, one appropriate shock was delivered
for every 2.5 implanted devices. Our appropriate annual ICD
therapy/discharge rate of 11.1% compares with the 8.6–
14.5% previously reported.22 The value of routine pro-
grammed electrical stimulation as part of risk stratiﬁcation
in patients without palpitations or pre-syncopal events with
LGE and LVEF > 35% remains to be determined.22
Our study supports the recommendations of the 2014 HRS
guidelines concerning the use of DECMR and device
implantation.22
The prognostic studies summarized in Table 1B generally
report LGE in 25–30% of unselected patients cohorts and uni-
formly conﬁrm the relationship between the extent of LGE
and adverse outcome. Our study conﬁrmed the favourable
prognosis of small, asymptomatic myocardial scars as previ-
ously reported.7,9,12–14 The remarkable difference between
our conclusions and those of Patel et al., who reported small
asymptomatic scar in patients with mildly impaired systolic
ventricular functions to be a strong risk factor for adverse
events, could partly be explained by a difference in patient
population and the distribution of LGE.4 Patel’s cohort mainly
consisted of African American women with RV LGE in 67%, a
potentially high-risk scenario. Long-term outcomes in patients
with CS have markedly improved because of modern heart
failure management, including device therapy and arrhythmia
ablation in selected patients.10,11,18,25,26 Current annual mor-
tality rates range from 0–4.2/100 patients compared with
7.5–12/100 patients as previously reported by Yazaki (2001)
and Fleming (1987).22 Our study is the ﬁrst to include data
on T2-weighted oedema imaging. Active myocardial inﬂam-
mation may increase arrhythmogenicity, but conﬂicting data
exist concerning the efﬁcacy of current immune-suppressive
and anti-arrhythmic treatment in actually improving long-
term outcomes in patients with active disease.11,12,18,22,24–26
The presence of increased T2 signal in our cohort, managed
with corticosteroids and methotrexate, did not correlate with
adverse events during follow-up. The accuracy for detecting
active granulomatous sarcoidosis with T2-weighted spin echo
sequences is however suboptimal, and we may well have
underestimated inﬂammatory changes.3 T2-mapping and
ﬂuorodeoxyglucose positron emission tomography (FDG-PET)
have shown promise in diagnosing active disease and guiding
immune-suppressive management and have replaced spin
echo assessment.2,12,18,27
Study limitations
Our study is limited by relatively small number of, predomi-
nantly Caucasian, patients and few events. African American
and Japanese populations generally have higher rates of car-
diac involvement with more extensive myocardial involve-
ment and possibly a more malignant course.4,7,12,26
Intermittent ambulatory rhythm monitoring may have missed
sVT. However, the long-term outcome in our cohort still
remained favourable. T1/T2 mapping would have increased
the detection of interstitial ﬁbrosis and inﬂammation and
have potentially increased prognostic accuracy.27,28
Conclusions
The LGE is the strongest, independent CMR predictor of fu-
ture adverse cardiac events in sarcoidosis patients. RV in-
volvement in addition to LV LGE increases risk of adverse
cardiac outcomes and death of all causes. DECMR should ide-
ally be performed in sarcoidosis patients with cardiac symp-
toms. Asymptomatic patients with LGE < 8% of LV mass
and mildly impaired LVEF may not beneﬁt from device ther-
apy and be monitored. Future prospective studies will help
determine the timing of DECMR studies. Current medical
management including device therapy has improved survival
in this condition.10,17,22,26
Perspectives
Biventricular myocardial LGE is the strongest, independent
CMR predictor of future adverse cardiac events in sarcoidosis
Right ventricular scar predicts outcome in sarcoidosis 169
ESC Heart Failure 2018; 5: 157–171
DOI: 10.1002/ehf2.12201
patients. DECMR should ideally be performed in every sar-
coidosis patient with cardiac symptoms and/or abnormal ba-
sic assessment. The presence of symptoms and extent of
LGE, and not predominantly LVEF, will guide the managing
clinician in when to implant an ICD. Asymptomatic Caucasian
patients with limited LGE < 8% of LV mass, and preserved
LVEF, may not beneﬁt from device therapy and can be safely
observed. Future research will focus on comprehensive diag-
nostic and prognostic strategies, which will include serologi-
cal markers of disease activity and heart failure, LGE
characteristics, and pre-contrast and post-contrast T1/T2
mapping to evaluate interstitial ﬁbrosis and extracellular ma-
trix volume. Hybrid PET-CMR imaging may optimize detec-
tion and management of active inﬂammation. DECMR may
help plan VT ablation and potentially increase success rates
and outcomes.
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